跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ADi
首页
药物
ADi
ADi
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Engineered chimeric pegylated ADI and methods of use
申请人: TDW GROUP
优先权: 2014
CN
US
2 件公开
3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors
申请人: PFIZER
优先权: 2001
US
4 件公开
Method for preparing immobilized arginine deiminase (ADI) and producing [14/15N]-L-citrulline
申请人: SHANGHAI UNIV OF MEDICINE&HEALTH SCIENCES
优先权: 2019
US
ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT
申请人: POLARIS GROUP
优先权: 2013
CN
EP
US
WO
7 件公开
ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT
申请人: POLARIS GROUP
优先权: 2014
CN
EP
US
5 件公开
PEG (polyethylene glycol) modified recombinant arginine deiminase (ADI) as well as preparation method and application thereof
申请人: UNIV JIANGNAN
优先权: 2014
CN
Methods of providing a fragrance to a composition and methods of enhancing fragrances using bicyclo[3.3.0]-oct(adi)ene hydroformylation products
申请人: COGNIS DEUTSCHLAND GMBH
优先权: 1998
US
Methods of providing a fragrance to a composition and methods of enhancing fragrances using (di)methyl-substituted cycloot(adi)ene hydroformylation products
申请人: COGNIS DEUTSCHLAND GMBH
优先权: 1998
US
药物
反馈